Guiding Target Selection and Lead Optimization for a PROTAC Targeted Protein Degrader

Webinar Details

Applying model-informed drug discovery and development (MID3) early in development can reduce late-stage risk by determining feasibility of drugging a given target, prioritizing between targets, or defining optimal drug properties for a target product profile. However, the lack of pharmacokinetic (PK) and pharmacodynamic (PD) data available at early stages can make modeling a challenge. For this reason, we developed Early Feasibility Assessment (EFA): a method for making effective dose predictions using mechanistic PK/PD models built from general biophysical principles and parameterized by data that is readily available early in drug discovery.  

Applied BioMath Assess™ is a point-and-click, MID3 software for performing EFA across various modalities. This webinar series will discuss scientific case studies demonstrating how you can quickly inform target selection, project clinical dose requirements, design a lead optimization funnel, and identify areas of program risk.  

This webinar will demonstrate how to use Applied BioMath's PROTAC Assess model to: 

  • Explore PROTAC binding parameters to optimize its potency
  • Evaluate the dependence of target expression and turnover on its degradation profile

The model is a cellular model of a targeted protein degrader (TPD). The TPD modeled is a proteolysis targeting chimeric (PROTAC), a heterobifunctional molecule that can bind to E3 ligase, target of interest, or both (forming a ternary complex). Formation of a ternary complex leads to target degradation. Model output is target expression over time. Additional targets of interest (up to 2) can be added to explore selectivity of TPD.

View the Webinar